Will Makary’s FDA Reforms Outlast His Tenure?
Marty Makary may not finish his term as FDA commissioner, but his time at the agency has already reshaped how it operates – from a sweeping integration of generative AI into the review process to a landmark MDUFA VI negotiation that industry veterans describe as the most collaborative in history.
In Vivo - May 12, 2026

Scrip Awards Podcast: Call For Entries 2026, New AI Category, Triana Interview
The Scrip Awards 2026 are now open for entries, with a debut for the AI in Drug Discovery Award, plus an interview with one of last year's winners.
Scrip - May 12, 2026

Bayer Back In The Market For Bolt-Ons
CEO Bill Anderson tells Scrip that there will be more deals of the size of the recent acquisition of Perfuse but ‘we're not willing to pay more than we believe something is worth.’
Scrip - May 12, 2026

New Product Launches Drive Celltrion’s Q1 Revenues
Celltrion’s “young” products accounted for 60% of quarterly revenues, with further growth opportunities expected in the second half of 2026.
Generics Bulletin - May 12, 2026

EU ePI Rollout Will Bypass Most OTCs Until 2027
Electronic product information won't reach most OTC medicines until H2 2027 at the earliest, and even then there's an unresolved scanning problem — leaving QR codes under updated EMA guidance as the practical option for now.
HBW Insight - May 12, 2026

Stock Watch: US Pharma Rescues Earnings Season As Lilly, AbbVie And BMS Beat
European big pharma financial reports dragged on first-quarter earnings season before AbbVie, Lilly and Bristol Myers Squibb brought a dose of investor enthusiasm.
Scrip - May 12, 2026

Podcast: Inside Arcutis with CEO Frank Watanabe
In this episode of the In Vivo podcast, Arcutis CEO Frank Watanabe talks culture, "patient?is?paramount" leadership, Zoryve's growth in inflammatory skin disease, and how he’s positioning the company for durable innovation and profitability.
In Vivo - May 12, 2026

Hengrui, BMS Strike Huge $15.2bn Alliance For Bundle Of Preclinical Assets
BMS and China’s Hengrui Pharmaceuticals team up in a large-scale R&D alliance covering a total of 13 programs to speed up the early-stage clinical development of preclinical assets originated by both firms across multiple therapeutic areas.
Scrip - May 12, 2026

Bridging The Reimbursement And Screening Gap: AstraZeneca’s Asia Strategy
AstraZeneca’s Area VP for Asia, Arun Krishna, talks about innovative financing, outcome-based pricing, democratizing diagnosis and AI-driven tools to bridge gaps in access and scale treatment across the diverse region. Paying for innovation is an asset not cost, he tells Scrip in an interview.
Scrip - May 12, 2026

Hengrui/Braveheart’s Myosin Inhibitor Shows nHCM Disease-Modifying Signal
Braveheart/Hengrui's cardiac myosin inhibitor HRS-1893 yielded both heart function improvements and cardiac structural reverse remodeling toward normal in a Phase II trial.
Scrip - May 12, 2026

Mounjaro Boosts Lilly’s Japan Sales But Price Cut Concerns Linger
Lilly's Japan business saw double-digit growth to an annual record, driven by Mounjaro for diabetes, but the US giant's country president expresses concern over potential reimbursement price cuts that would de-incentivize innovative products.
Scrip - May 12, 2026

Skinny Label At SCOTUS: Could Generics Maintain Carve-Out Authority No Matter The Decision?
Hikma could lose the monumental skinny label carve out case against Amarin at the US Supreme Court, but maintain its and other generic drug sponsors’ ability to market products with patented indications carved out.
In Vivo - May 12, 2026

Roche’s Alzheimer’s Blood Test Achieves CE Marking, One Day After Fujirebio
Roche’s Elecsys pTau217, co-developed with Eli Lilly, uses a dual-cutoff approach and — unlike Fujirebio’s rival test — is cleared for primary care.
Medtech Insight - May 12, 2026

Gifrer Acquisition To Boost Celltrion’s French Reach, Portfolio
Celltrion acquiring Gifrer to strengthen its commercial footprint in France, better respond to the French government's biosimilar substitution policy and diversify its product portfolio beyond prescription biologics.
Scrip - May 12, 2026